News and Announcements
New Investor Presentation from Prescient Therapeutics
- Published November 04, 2015 4:43PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
4th November 2015, ASX Announcement
Prescient Therapeutics have today released a new Investor Presentation. which can be viewed by clicking here.
ABOUT PRESCIENT THERAPEUTICS
Prescient Therapeutics (formerly Virax Holdings) is a clinical stage oncology company developing novel targeted approaches to treat cancers of high unmet need, such as advanced breast, ovarian, multiple myeloma and acute leukemia.
The company raised A$3M in June 2014 and has in the last 6-months acquired a deep pipeline of products through strategic company acquisitions. Prescients’ pipeline includes a small molecule inhibitor PTX-100 (GGTI 2418), capable of blocking the Ras cancer pathway as well as PTX-200 (TCN-P) which inhibits the AKT pathway, another key pathway that contributes to cancer.
Together these novel drugs provide Prescient the unique ability to run five active clinical trials, within the next 12-months, at some of the worlds best Cancer Centers. The aim is to bring to provide better outcomes for cancer patients around the world.